[HTML][HTML] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
M Gogishvili, T Melkadze, T Makharadze… - Nature medicine, 2022 - nature.com
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
M Gogishvili, T Melkadze, T Makharadze… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
[PDF][PDF] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
M Gogishvili, T Melkadze, T Makharadze, D Giorgadze… - academia.edu
Results Patient characteristics. In total, 904 patients were screened for enrollment at 74 sites
in ten countries (Supplementary Table 1). Between 17 June 2019 and 30 September 2020 …
in ten countries (Supplementary Table 1). Between 17 June 2019 and 30 September 2020 …
[HTML][HTML] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
M Gogishvili, T Melkadze, T Makharadze… - Nature …, 2022 - ncbi.nlm.nih.gov
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
M Gogishvili, T Melkadze, T Makharadze… - Nature …, 2022 - europepmc.org
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …